trending Market Intelligence /marketintelligence/en/news-insights/trending/TCPZK0_o-z0wx1iCQZ_8EA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA grants priority review to Portola's drug application for betrixaban

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA grants priority review to Portola's drug application for betrixaban

The U.S. FDA granted priority review to Portola Pharmaceuticals Inc.'s new drug application for betrixaban.

Betrixaban, an FDA-designated fast track investigational drug, is a Factor Xa inhibitor anticoagulant for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for venous thromboembolism.

A priority review shortens the agency's review timeline to six months from the standard review period of 10 months. The application for the drug was deemed sufficiently complete to allow a substantive review and was given an approval date of June 24, 2017.

In addition, the European Medicines Agency has validated Portola's marketing authorization application for betrixaban. The EMA's committee for medicinal products for human use is reviewing the application under a standard 210-day review period.